

# Top 200 Drugs by Retail Sales in 2023

Compiled and Produced by Ryan E. Williams and Hayden M. Leatherwood from the Njarðarson Group (The University of Arizona)

1 <b>Keytruda</b> (Pembrolizumab) \$20.1 Billion Oncology 	2 <b>Eliquis</b> (Apixiban) \$11.953 Billion Cardiology/Vascular Diseases 	3 <b>Ozempic</b> (Semaglutide) \$18.468 Billion Cardiology/Vascular Diseases 	4 <b>Humira</b> (Adalimumab) \$14.494 Billion Immunology 	5 <b>Biktarvy</b> (Bictegravir/Emtricitabine/Tenofovir Alafenamide) \$11.852 Billion Rare Diseases 	6 <b>Dupixent</b> (Dupilumab) \$11.565 Billion Immunology 	7 <b>Stelara</b> (Ustekinumab) \$11.297 Billion Immunology 	8 <b>Comirnaty</b> (COVID-19 Vaccine, mRNA) \$11.220 Billion Infectious Diseases 	9 <b>Jardiance</b> (Empagliflozin) \$10.600 Billion Diabetes 	10 <b>Opdivo</b> (Nivolumab) \$10.010 Billion Immunology 	11 <b>Darzalex</b> (Daratumumab) \$9.744 Billion Immunology 	12 <b>Eylea</b> (Aflibercept) \$9.225 Billion Ophthalmology 	13 <b>Trikafta</b> (Elexacaftor/Zincacfton/Vaccinia) \$8.864 Billion Rare Diseases 	14 <b>Gardasil</b> (HPV Quadrivalent Vaccine) \$8.864 Billion Infectious Diseases 	15 <b>Skyrizi</b> (Risankizumab) \$7.763 Billion Immunology 	16 <b>Ocrevus</b> (Ocrelizumab) \$7.403 Billion Immunology 	17 <b>Trulicity</b> (Dulaglutide) \$7.132 Billion Diabetes 	18 <b>Insulin</b> (Insulin) \$6.979 Billion Diabetes 	19 <b>Imbruvica</b> (Ibrutinib) \$6.979 Billion Oncology 	20 <b>Xarelto</b> (Rivaroxaban) \$6.793 Billion Cardiology/Vascular Diseases 
21 <b>Prevnar Family</b> (Pneumococcal 7-Valent Conjugate) \$6.640 Billion Infectious Diseases 	22 <b>Revlimid</b> (Lenalidomide) \$6.179 Billion Oncology 	23 <b>Entresto</b> (Sacubitril/Valsartan) \$6.035 Billion Cardiology/Vascular Diseases 	24 <b>Xtandi</b> (Enzalutamide) \$5.971 Billion Oncology 	25 <b>Farigra</b> (Dapagliflozin) \$5.963 Billion Diabetes 	26 <b>Tagrisso</b> (Osimertinib) \$5.799 Billion Oncology 	27 <b>Botox</b> (OnabotulinumtoxinA) \$5.673 Billion Neurology 	28 <b>Entyvio</b> (Vedolizumab) \$5.280 Billion Immunology 	29 <b>Mounjaro</b> (Tirzepatide) \$5.163 Billion Diabetes 	30 <b>Cosentyx</b> (Secukinumab) \$4.980 Billion Immunology 	31 <b>Hemlibra</b> (Emicizumab) \$4.811 Billion Rare Diseases 	32 <b>Ibrance</b> (Trastuzumab) \$4.753 Billion Oncology 	33 <b>Enbrel</b> (Etanercept) \$4.527 Billion Immunology 	34 <b>Perjeta</b> (Pertuzumab) \$4.371 Billion Oncology 	35 <b>Tecentriq</b> (Atezolizumab) \$4.369 Billion Oncology 	36 <b>Imfinzi</b> (Durvalumab) \$4.237 Billion Oncology 	37 <b>Immunoglobulin</b> (Immunoglobulin) \$4.210 Billion Immunology 	38 <b>NovoRapid</b> (Insulin Aspart) \$4.177 Billion Diabetes 	39 <b>Invega Sustenna</b> (Paliperidone Palmitate) \$4.115 Billion Neurology 	40 <b>Prolia</b> (Denosumab) \$4.049 Billion Musculoskeletal 
41 <b>Lynparza</b> (Olaparib) \$4.010 Billion Oncology 	42 <b>Xolair</b> (Omalizumab) \$3.987 Billion Immunology 	43 <b>Rinvoq</b> (Upadacitinib) \$3.969 Billion Immunology 	44 <b>Verzenio</b> (Abiraterone) \$3.863 Billion Oncology 	45 <b>Ofev</b> (Nintedanib) \$3.728 Billion Respiratory Diseases 	46 <b>Shingrix</b> (Zoster Vaccine Recombinant, Adjuvanted) \$3.717 Billion Infectious Diseases 	47 <b>Orencia</b> (Abatacept) \$3.601 Billion Immunology 	48 <b>Pomalyst</b> (Pomalidomide) \$3.441 Billion Oncology 	49 <b>Vyndaqel</b> (Tofacitinib) \$3.321 Billion Rare Diseases 	50 <b>Tremfya</b> (Guselkumab) \$3.147 Billion Immunology 	51 <b>Soliris</b> (Eculizumab) \$3.145 Billion Rare Diseases 	52 <b>Actemra</b> (Tocilizumab) \$3.001 Billion Immunology 	53 <b>Yvyanse</b> (Ulvacemafoline) \$2.965 Billion Immunology 	54 <b>Ultomiris</b> (Rovatriumab-cvz) \$2.945 Billion Immunology 	55 <b>Lenvima</b> (Lenvatinib) \$2.868 Billion Oncology 	56 <b>Taltz</b> (Tegaserod) \$2.739 Billion Oncology 	57 <b>Vraylar</b> (Cariprazine) \$2.739 Billion Oncology 	58 <b>Vabysmo</b> (Faricimab) \$2.724 Billion Oncology 	59 <b>Rybelsus</b> (Eliquis) \$2.725 Billion Diabetes 	60 <b>Calquence</b> (Acetabiphenol) \$2.514 Billion Oncology 
61 <b>Erihepa</b> (ApoE2/ApoB) \$2.387 Billion Oncology 	62 <b>Trelegy Eliпта</b> (Fluticasone/Vilanterol/Umeciclib) \$2.376 Billion Respiratory Diseases 	63 <b>Symbicort</b> (Formoterol/Formoterol) \$2.362 Billion Respiratory Diseases 	64 <b>Enbretu</b> (Trafurumab Denifabecan) \$2.349 Billion Oncology 	65 <b>Venclexta</b> (Vandetanib) \$2.288 Billion Oncology 	66 <b>Kadcyla</b> (Trastuzumab Emtansine) \$2.280 Billion Oncology 	67 <b>Promacta</b> (Elinogrel) \$2.269 Billion Oncology 	68 <b>Cimzia</b> (Certolizumab Pegol) \$2.255 Billion Immunology 	69 <b>Yervoy</b> (Ipilimumab) \$2.238 Billion Immunology 	70 <b>Remicade</b> (Infliximab) \$2.233 Billion Immunology 	71 <b>Xgeva</b> (Ezetimib) \$2.212 Billion Oncology 	72 <b>Simponi</b> (Golimumab) \$2.197 Billion Immunology 	73 <b>Januvia</b> (Sitagliptin) \$2.189 Billion Diabetes 	74 <b>Otezla</b> (Apremilast) \$2.188 Billion Immunology 	75 <b>Vekury</b> (Vandetanib) \$2.184 Billion Oncology 	76 <b>Kesimpta</b> (Oprelvekin) \$2.171 Billion Immunology 	77 <b>Kisqali</b> (Ribicicli) \$2.090 Billion Oncology 	78 <b>Rexulti</b> (Ibragadol) \$2.099 Billion Neurology 	79 <b>Genyoiva</b> (Zinc Polysulfate) \$2.060 Billion Oncology 	80 <b>Lucentis</b> (Ranibizumab) \$2.008 Billion Ophthalmology 
81 <b>Descovy</b> (Emtricitabine/Tenofovir Alafenamide) \$1.983 Billion Infectious Diseases 	82 <b>Opsumit</b> (Macitentan) \$1.978 Billion Cardiology/Vascular Diseases 	83 <b>Dovato</b> (Dolutegravir/Lamivudine) \$1.963 Billion Rare Diseases 	84 <b>Sprycel</b> (Dasatinib) \$1.950 Billion Oncology 	85 <b>Tafinlar</b> (Dabrafenib/Trafetinib) \$1.922 Billion Oncology 	86 <b>MabThera</b> (Rituximab) \$1.891 Billion Oncology 	87 <b>Herceptin</b> (Trastuzumab) \$1.868 Billion Oncology 	88 <b>Tysabri</b> (Natalizumab) \$1.876 Billion Immunology 	89 <b>Prezista</b> (Darunavir/Cobicistat) \$1.854 Billion Rare Diseases 	90 <b>Tasigna</b> (Nilotinib) \$1.848 Billion Oncology 	91 <b>Bridion</b> (Sugammadex) \$1.842 Billion Immunology 	92 <b>Ingrezza</b> (Valproic Acid) \$1.836 Billion Immunology 	93 <b>Avastin</b> (Bevacizumab) \$1.825 Billion Oncology 	94 <b>Trajenta</b> (Linagliptin/Metformin) \$1.815 Billion Diabetes 	95 <b>Gilenya</b> (Fingolimod) \$1.811 Billion Immunology 	96 <b>Nucala</b> (Mepolizumab) \$1.786 Billion Neurology 	97 <b>Alecensa</b> (Alectinib) \$1.742 Billion Oncology 	98 <b>Spiranza</b> (Nivolumab) \$1.741 Billion Oncology 	99 <b>Jakavi</b> (Ruxofitinib) \$1.720 Billion Oncology 	100 <b>Lixiana</b> (Edoxaban) \$1.720 Billion Oncology 
101 <b>Xeljanz</b> (Tofacitinib) \$1.703 Billion Immunology 	102 <b>Zyprexa</b> (Olanzapine) \$1.694 Billion Neurology 	103 <b>Trimec</b> (Abacavir/Dolutegravir/Lamivudine) \$1.664 Billion Rare Diseases 	104 <b>Humalog</b> (Insulin Lispro) \$1.663 Billion Diabetes 	105 <b>Erysdi</b> (Risipidol) \$1.646 Billion Neurology 	106 <b>Repatha</b> (Evolocumab) \$1.635 Billion Cardiology/Vascular Diseases 	107 <b>Upravi</b> (Seligyl) \$1.582 Billion Cardiology/Vascular Diseases 	108 <b>Creon</b> (Pancrelipase) \$1.572 Billion Rare Diseases 	109 <b>Lipitor</b> (Atorvastatin) \$1.559 Billion Cardiology/Vascular Diseases 	110 <b>Fasena</b> (Benralizumab) \$1.553 Billion Respiratory Diseases 	111 <b>Eplusa</b> (Sildenafil/Vasopressin) \$1.537 Billion Infectious Diseases 	112 <b>Lantus</b> (Insulin Glargine) \$1.532 Billion Diabetes 	113 <b>Yescarta</b> (Axicicabtagene Caricel) \$1.499 Billion Oncology 	114 <b>Tivicy</b> (Dolutegravir) \$1.495 Billion Infectious Diseases 	115 <b>Sarenda</b> (Jaguglutide) \$1.495 Billion Nutritional Deficiency 	116 <b>Kyprolis</b> (Cariprazine) \$1.478 Billion Oncology 	117 <b>Nplate</b> (Romiplostim) \$1.477 Billion Immunology 	118 <b>Benlysta</b> (Belimumab) \$1.456 Billion Immunology 	119 <b>Mavyret</b> (Glecaprevir/Pasoprevir) \$1.430 Billion Oncology 	120 <b>Lagevrio</b> (Mogamulot) \$1.429 Billion Infectious Diseases 
121 <b>Brukisna</b> (Zinc Polysulfate) \$1.396 Billion Rare Diseases 	122 <b>Juvederm</b> (Hyaluronic Acid) \$1.376 Billion Oncology 	123 <b>Spiriva</b> (Tiotropium Bromide) \$1.376 Billion Respiratory Diseases 	124 <b>Prograf</b> (Tacrolimus) \$1.365 Billion Oncology 	125 <b>Aranesp</b> (Darbepoetin Alfa) \$1.362 Billion Oncology 	126 <b>Activase</b> (Alteplase/Tenecteplase) \$1.360 Billion Cardiology/Vascular Diseases 	127 <b>Ilaris</b> (Canakinumab) \$1.358 Billion Immunology 	128 <b>Abilify Maintena</b> (Aripiprazole) \$1.350 Billion Rare Diseases 	129 <b>Odefsey</b> (Emtricitabine/Rilpivirine/Atazanavir) \$1.330 Billion Rare Diseases 	130 <b>Adempas</b> (Riociclat) \$1.338 Billion Cardiology/Vascular Diseases 	131 <b>Brillinta</b> (Ticagrelor) \$1.324 Billion Oncology 	132 <b>Sandoctatin</b> (Octreotide) \$1.314 Billion Diabetes 	133 <b>Mirena</b> (Levonorgestrel) \$1.311 Billion Respiratory Diseases 	134 <b>Phesgo</b> (Perflubron/Perfloran/Perfloran) \$1.299 Billion Immunology 	135 <b>Betanis</b> (Nifedipine) \$1.283 Billion Immunology 	136 <b>Nexgard</b> (Eprinomaxone) \$1.282 Billion Immunology 	137 <b>Paxlovid</b> (Ritonavir/Simeprevir) \$1.279 Billion Infectious Diseases 	138 <b>Xywav</b> (Cic. Mfg. K and Na Oxibutate) \$1.272 Billion Immunology 	139 <b>Victoza</b> (Liraglutide) \$1.259 Billion Diabetes 	140 <b>Seretide</b> (Salmeterol) \$1.229 Billion Oncology 
141 <b>Austedo</b> (Doxylamine) \$1.225 Billion Neurology 	142 <b>Evenity</b> (Romosozumab) \$1.224 Billion Musculoskeletal 	143 <b>Jynarque</b> (Sitagliptin) \$1.223 Billion Diabetes 	144 <b>Reblozyl</b> (Luspatercept) \$1.220 Billion Hematology 	145 <b>AbraXane</b> (Pegfilgrastim) \$1.216 Billion Oncology 	146 <b>Loxenol</b> (Enalapril) \$1.214 Billion Cardiology/Vascular Diseases 	147 <b>Zolgensma</b> (Onasemnogene Apheresis Concentrate) \$1.214 Billion Neurology 	148 <b>Toujeo</b> (Insulin Glargine) \$1.212 Billion Diabetes 	149 <b>Relvar</b> (Riluzole/Fosfociclit) \$1.190 Billion Cardiology/Vascular Diseases 	150 <b>Janumet</b> (Sitagliptin/Metformin) \$1.177 Billion Diabetes 	151 <b>Talkzyro</b> (Lansoprazole/Ramipril) \$1.168 Billion Cardiology/Vascular Diseases 	152 <b>Vectibix</b> (Panitumumab) \$1.162 Billion Oncology 	153 <b>Strensiq</b> (Aldesleukin) \$1.152 Billion Immunology 	154 <b>Somatuline</b> (Lacosamide) \$1.150 Billion Oncology 	155 <b>Edurant</b> (Bictegravir) \$1.150 Billion Rare Diseases 	156 <b>Tresiba</b> (Insulin Degludec) \$1.126 Billion Diabetes 	157 <b>Covid-19 Vaccine</b> (Ad26.COV2.S (recombinant)) \$1.117 Billion Infectious Diseases 	158 <b>Crestor</b> (Rosuvastatin) \$1.113 Billion Cardiology/Vascular Diseases 	159 <b>Linzess</b> (Linaclotide) \$1.108 Billion Gastrointestinal Diseases 	160 <b>Crysvita</b> (Bimatoprost) \$1.103 Billion Ophthalmology 
161 <b>Fabrazyme</b> (Agalsidase Beta) \$1.069 Billion Oncology 	162 <b>Trodely</b> (Saccharum Gaviscon) \$1.063 Billion Immunology 	163 <b>Inlyta</b> (Axitinib) \$1.036 Billion Oncology 	164 <b>Aubagio</b> (Teriflunomide) \$1.020 Billion Neurology 	165 <b>Plavix</b> (Clopidogrel) \$1.023 Billion Cardiology/Vascular Diseases 	166 <b>Tecfidera</b> (Dimethyl Fumarate) \$1.012 Billion Oncology 	167 <b>Simponi</b> (Golimumab) \$1.002 Billion Immunology 	168 <b>Pluvicto</b> (Lutetium-177 vipivotide Tetroxetan) \$980 Million Oncology 	169 <b>Cyramza</b> (Ramuciclib) \$974 Million Immunology 	170 <b>Polyvy</b> (Polizumab Vedotin-pik) \$971 Million Oncology 	171 <b>Zoladex</b> (Goserelin) \$932 Million Oncology 	172 <b>Nexium</b> (Esomeprazole) \$945 Million Gastrointestinal Diseases 	173 <b>Nubeqa</b> (Darolutamide) \$942 Million Immunology 	174 <b>Gazyva</b> (Obinutuzumab) \$940 Million Immunology 	175 <b>Nurec ODT</b> (Rimegepant) \$928 Million Immunology 	176 <b>Olumiant</b> (Jabliricic) \$922 Million Immunology 	177 <b>Bilcyto</b> (Bimatoprost) \$919 Million Ophthalmology 	178 <b>Bexsero</b> (Meningococcal Vaccine) \$918 Million Infectious Diseases 	179 <b>Praxida</b> (Dabigatran Etexilate) \$899 Million Hematology 	180 <b>Albumin</b> (Albumin) \$887 Million Rare Diseases 
181 <b>Zytiga</b> (Abiraterone Acetate) \$887 Million Oncology 	182 <b>Libtayo</b> (Campidomide) \$863 Million Oncology 	183 <b>Vemlidy</b> (Tenofovir Disoproxil) \$862 Million Infectious Diseases 	184 <b>Humulin</b> (Insulin Isophane) \$852 Million Diabetes 	185 <b>Epidiolex</b> (Cannabidiol) \$845 Million Neurology 	186 <b>Myozyme</b> (Agalsidase Alfa) \$845 Million Rare Diseases 	187 <b>Nexplanon</b> (Etonogestrel) \$830 Million Women's Health 	188 <b>Advate</b> (Factorial Factor (Recombinant)) \$818 Million Rare Diseases 	189 <b>Ubrovity</b> (Ubrogepant) \$815 Million Neurology 	190 <b>Avonex</b> (Interferon Beta-1a) \$811 Million Neurology 	191 <b>Ventolin</b> (Albuterol) \$808 Million Respiratory Diseases 	192 <b>Kogenate</b> (Factorial Factor (Recombinant)) \$800 Million Rare Diseases 	193 <b>Alprolix</b> (Factorial Factor (Recombinant)) \$786 Million Rare Diseases 	194 <b>Concerta</b> (Methylphenidate) \$783 Million Neurology 	195 <b>Takecab</b> (Voprisartan) \$780 Million Gastrointestinal Diseases 	196 <b>Synagis</b> (Palivizumab) \$778 Million Immunology 	197 <b>Cabenuva</b> (Clobetasol Propionate) \$764 Million Infectious Diseases 	198 <b>Suplerzon</b> (Calcipotriol/Calcipotriol) \$764 Million Infectious Diseases 	199 <b>Acetris</b> (Bendamustine Hydrochloride) \$744 Million Oncology 	200 <b>Cerezyme</b> (Imiglucerase) \$741 Million Rare Diseases 

Key: Oncology, Immunology, Infectious Diseases, Neurology, Diabetes, Cardiology/Vascular Diseases, Rare Diseases, Respiratory Diseases, Hematology, Gastrointestinal Diseases, Musculoskeletal, Other